Edition:
United Kingdom

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.18EUR
23 Feb 2018
Change (% chg)

€-0.43 (-4.94%)
Prev Close
€8.60
Open
€8.60
Day's High
€8.68
Day's Low
€7.82
Volume
2,520,614
Avg. Vol
483,999
52-wk High
€16.88
52-wk Low
€7.28

Latest Key Developments (Source: Significant Developments)

Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain
Friday, 22 Dec 2017 

Dec 22 (Reuters) - ALMIRALL SA ::EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN).LICENSE AGREEMENT GRANTS ALMIRALL EXCLUSIVE RIGHTS TO COMMERCIALIZE CRESTOR AND PROVISACOR IN SPAIN.  Full Article

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALMIRALL SA ::ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​.TUDORZA REDUCES CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND DEMONSTRATES CARDIOVASCULAR SAFETY.‍​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Almirall says Tildrakizumab launch in Europe moved to end-2018 or early 2019‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ALMIRALL SA ::SAYS ANTICIPATED APPROVAL FOR TILDRAKIZUMAB AND ITS LAUNCH IN EUROPE ARE MOVED FROM MID-2018 TO END OF 2018 OR EARLY 2019.‍​.  Full Article

Almirall 9-month net result turns to loss of 99.7 mln euros YoY
Monday, 6 Nov 2017 

Nov 6 (Reuters) - ALMIRALL SA ::9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO.9-MONTH REVENUE 561.6 MILLION EUROS VERSUS 635.4 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 99.7 MILLION EUROS VERSUS PROFIT 103.5 MILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT EXPENSES 67.2 MILLION EUROS VERSUS 61.8 MILLION EUROS YEAR AGO.REITERATES ESTIMATES ANNOUNCED ON JULY 10.  Full Article

Almirall ends phase III research for nail psoriasis product in Europe
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - ALMIRALL SA ::TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT.  Full Article

Almirall reduces FY 2017 revenue, net sales and EBITDA growth estimates
Monday, 10 Jul 2017 

July 10 (Reuters) - ALMIRALL SA ::PROVIDES UPDATE TO FY 2017 GUIDANCE THAT REDUCES INITIAL ESTIMATIONS FOR TOTAL REVENUES, NET SALES AND EBITDA GROWTH.SAYS FY 2017 GUIDANCE UPDATE TO TAKE ACCOUNT OF ADVERSE IMPACT OF RECENT MARKET DEVELOPMENTS IN US DERMATOLOGY.SEES FY 2017 EBITDA OF 140-170 MILLION EUROS.SEES LOW DOUBLE DIGIT DECLINE OF FY 2017 TOTAL REVENUE AND NET SALES VERSUS FY 2016.SAYS INVENTORY DESTOCKING, INAPPROPRIATE ADJUDICATION OF PATIENT ASSISTANCE PROGRAM AND GENERIC ACTICLATE WILL ADVERSELY IMPACT THE EARNINGS IN 2017.SAYS ITS BUSINESS IS PERFORMING IN LINE WITH EXPECTATIONS IN EUROPE AND REST OF THE WORLD.  Full Article

Almirall signs strategic deal with Nuevolution for skin diseases treatment
Monday, 12 Dec 2016 

Almirall SA : Signs strategic deal with Nuevolution for the treatment of inflammatory skin diseases and psoriatic arthritis . Nuevolution will receive an initial payment of 11.2 million euros ($11.9 million) and may receive additional payments for development and regulatory milestones of up to 172 million euros . Says agreement with Nuevolution could generate commercial milestones of up to 270 million euros .Nuevolution would also be entitled to receive royalties on the level of future net sales.  Full Article

Almirall announces positive phase III results for drug against psoriasis
Wednesday, 28 Sep 2016 

Almirall SA : Announces positive results from the phase III trial showing efficacy of dimethyl fumarate, a new systemic oral drug for patients with chronic plaque psoriasis .To present the results on Sep. 29 at the dermatology congress in Vienna.  Full Article

BRIEF-Almirall Sees 20 Pct EBITDA Growth In 2018

* FY EBITDA 142.2 MILLION EUROS VERSUS 227.6 MILLION EUROS YEAR AGO